Physician profile
Charles Pope
NPI 1639351059
$10,586.78
in general payments reported to CMS, 2019-2025
50 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,210 · 2022: $2,936 · 2023: $1,998 · 2024: $1,822 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,440.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,493.66 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $679.06 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Amgen INC. | $623.93 | 2021-2025 | Uplizna, Aimovig |
| Biogen, INC. | $619.94 | 2021-2025 | Leqembi, Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $463.51 | 2021-2025 | |
| Pfizer INC. | $422.06 | 2023-2025 | |
| Lilly USA, LLC | $403.69 | 2021-2024 | Amyvid, Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $394.25 | 2022 | |
| Lundbeck LLC | $381.15 | 2022-2025 | Vyepti, Rexulti |
| Kyowa Kirin, INC. | $379.22 | 2021-2024 | Nourianz |
| Genzyme Corporation | $371.89 | 2021-2023 | |
| Merz Pharmaceuticals, LLC | $308.04 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Allergan, INC. | $300.16 | 2021-2022 | |
| Sk Life Science, INC. | $284.19 | 2021-2024 | |
| Boston Scientific Corporation | $274.30 | 2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.